DRL receives USFDA approval for Tosymra – migraine spray


Dr Reddy’s Laboratories Ltd has received USFDA approval for ‘Tosymra’ spray which is used to treat acute migraine with or without aura in adults.
The medicinal spray previously known as DFN-02 is formulated using a proprietary novel excipient known as Intravail to achieve blood levels similar to a 4-mg sumatriptan subcutaneous injection, resulting in rapid onset of action. As of January 2019, the product is yet to be commercialized.

Company Profile : Dr Reddys Laboratories Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.